Skip to content

Effectiveness of tDCS on cognitive function in patients of Alzheimers Disease

Study of Effectiveness of transcranial direct current stimulation (tDCS) on cognitive function in patients of Alzheimer's Disease: A double blind sham controlled randomized trial - NIL

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/096938
Enrollment
66
Registered
2025-11-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G30- Alzheimers disease

Interventions

Intervention1: Transcranial Direct current stimulation (tDCS): The Anode electrode and the cathode electrode will be placed over the left dorsolateral prefrontal cortex and over the right supraorbita

Sponsors

SELF
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A : Patients diagnosed with Alzheimer s disease according to standardized diagnostic criteria (ICD-11). B : Patients who will give informed consent. C : Patients between the ages of 60 years and 80 years. D : Patients on Donepezil for a minimum of 4 weeks with MMSE Score between 18-23.

Exclusion criteria

Exclusion criteria: A : Age below 60 years and above 80 years B : Patients with a history of significant neurological disorders other than dementia (e.g. Traumatic Head Injury, epilepsy). C : Individuals with severe psychiatric conditions (e.g., schizophrenia, Mental retardation, Mood Disorders) D : Individual who was previously diagnosed with Wernicke s Koraskoff Psychosis E : Those with contraindications to tDCS (transcranial direct current stimulation), such as implanted electronic devices. F : Inability to undergo the required cognitive assessments due to language barriers, severe sensory impairments, or other factors affecting comprehension or communication.

Design outcomes

Primary

MeasureTime frame
Effect of tDCS on cognitive function in patients of alzheimers disease Scales : ACE-III,MMSE,CGI and side effectsTimepoint: At Baseline, after 4 weeks [total 40 sessions (twice daily 5 days per week x 4 week)] and after 8 week.

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactProf Dr Suvendu Narayan Mishra

INSTITUTE OF MEDICAL SCIENCES (IMS) AND SUM HOSPITAL

dr.sar07@gmail.com9861273580

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026